MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts - PubMed (original) (raw)

Case Reports

MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts

A Chomyn et al. Proc Natl Acad Sci U S A. 1992.

Abstract

The pathogenetic mechanism of the mitochondrial tRNA(LeuUUR) gene mutation responsible for the MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes) syndrome was investigated in transformants obtained by transfer of mitochondria from three genetically unrelated MELAS patients into human mitochondrial DNA (mtDNA)-less (rho 0) cells. Marked defects in mitochondrial protein synthesis and respiratory activity were observed in transformants containing virtually pure mutant mtDNA, as compared to the parent of the rho 0 cells (the 143B cell line) or to transformants containing exclusively wild-type mtDNA, derived from one of the patients or a maternally related asymptomatic individual. A striking protective effect against the mutation was exerted in the transformants by levels of residual wild-type mtDNA above 6%. The MELAS mutation occurs within the mtDNA binding site for a protein factor (mTERF) that promotes termination of transcription at the 16S rRNA/tRNA(LeuUUR) gene boundary. A marked decrease in affinity of purified mTERF for the mutant target sequence was observed in in vitro assays. By contrast, RNA transfer hybridization experiments failed to show any significant change in the steady-state amounts of the two rRNA species, encoded upstream of the termination site, and of the mRNAs encoded downstream, in the transformants carrying the MELAS mutation.

PubMed Disclaimer

Cited by

Screening of effective pharmacological treatments for MELAS syndrome using yeasts, fibroblasts and cybrid models of the disease.
Garrido-Maraver J, Cordero MD, Moñino ID, Pereira-Arenas S, Lechuga-Vieco AV, Cotán D, De la Mata M, Oropesa-Ávila M, De Miguel M, Bautista Lorite J, Rivas Infante E, Alvarez-Dolado M, Navas P, Jackson S, Francisci S, Sánchez-Alcázar JA. Garrido-Maraver J, et al. Br J Pharmacol. 2012 Nov;167(6):1311-28. doi: 10.1111/j.1476-5381.2012.02086.x. Br J Pharmacol. 2012. PMID: 22747838 Free PMC article.
Effects on mitochondrial transcription of manipulating mTERF protein levels in cultured human HEK293 cells.
Hyvärinen AK, Kumanto MK, Marjavaara SK, Jacobs HT. Hyvärinen AK, et al. BMC Mol Biol. 2010 Sep 16;11:72. doi: 10.1186/1471-2199-11-72. BMC Mol Biol. 2010. PMID: 20846394 Free PMC article.
Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity.
Calabrese V, Scapagnini G, Giuffrida Stella AM, Bates TE, Clark JB. Calabrese V, et al. Neurochem Res. 2001 Jun;26(6):739-64. doi: 10.1023/a:1010955807739. Neurochem Res. 2001. PMID: 11519733 Review.
Mitochondrial DNA mutations in human disease.
Taylor RW, Turnbull DM. Taylor RW, et al. Nat Rev Genet. 2005 May;6(5):389-402. doi: 10.1038/nrg1606. Nat Rev Genet. 2005. PMID: 15861210 Free PMC article. Review.
Measurement of ATP production in mitochondrial disorders.
Shepherd RK, Checcarelli N, Naini A, De Vivo DC, DiMauro S, Sue CM. Shepherd RK, et al. J Inherit Metab Dis. 2006 Feb;29(1):86-91. doi: 10.1007/s10545-006-0148-8. J Inherit Metab Dis. 2006. PMID: 16601873

References

1. Basic Appl Histochem. 1986;30(2):153-63 - PubMed
1. EMBO J. 1990 Oct;9(10):3405-11 - PubMed
1. Ann Neurol. 1986 Nov;20(5):573-82 - PubMed
1. Science. 1989 Oct 27;246(4929):500-3 - PubMed
1. Cell. 1989 Jul 28;58(2):391-7 - PubMed

MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts - PubMed (original) (raw)